Search Team

Search by Last Name
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

Fish Cases

Allergan Inc., et al. v. Alcon Laboratories, et al.

Hatch-Waxman

Fish Cases

Allergan Inc., et al. v. Alcon Laboratories, et al.

Hatch-Waxman

Back to Case Listing

Counsel for Allergan in series of cases regarding ANDAs and 505(b)(2) NDAs for Allergan’s glaucoma drugs, ALPHAGAN® and ALPHAGAN® P 0.15%. Cases involving ALPHAGAN® resulted in landmark rulings on the permissible assertion of method-of use patents under the Hatch-Waxman Act. Case involving ALPHAGAN® P 0.15.% resulted in settlement on the morning of opening statements with defendant agreeing not to launch competitive drug for several years and to pay royalty on release.

In-Depth

Counsel for Allergan in series of cases regarding ANDAs and 505(b)(2) NDAs for Allergan’s glaucoma drugs, ALPHAGAN® and ALPHAGAN® P 0.15%. Cases involving ALPHAGAN® resulted in landmark rulings on the permissible assertion of method-of use patents under the Hatch-Waxman Act. Case involving ALPHAGAN® P 0.15.% resulted in settlement on the morning of opening statements with defendant agreeing not to launch competitive drug for several years and to pay royalty on release.